Ginkgo Bioworks (DNA) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Ginkgo Bioworks is projected to report its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($1.44) per share and revenue of $41.60 million.
• The company had previously reported a larger loss of ($1.58) EPS in its last quarter, missing expectations and showing a negative return on equity of 52.35%.
• Institutional investors control 78.63% of Ginkgo Bioworks' shares, with significant stake increases from firms like Goldman Sachs and AQR Capital Management in the first quarter.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Ginkgo Bioworks to post earnings of ($1.44) per share and revenue of $41.60 million for the quarter.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). The business had revenue of $48.32 million for the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. On average, analysts expect Ginkgo Bioworks to post $-10 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Ginkgo Bioworks Price Performance

NYSE DNA traded down $0.33 during trading on Wednesday, reaching $13.95. 1,152,532 shares of the company's stock were exchanged, compared to its average volume of 1,523,459. Ginkgo Bioworks has a fifty-two week low of $5.00 and a fifty-two week high of $16.85. The business has a 50 day moving average price of $10.33 and a 200-day moving average price of $9.40. The stock has a market capitalization of $816.49 million, a P/E ratio of -1.52 and a beta of 1.50.

Institutional Investors Weigh In On Ginkgo Bioworks

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its position in shares of Ginkgo Bioworks by 322.6% during the 1st quarter. AQR Capital Management LLC now owns 158,939 shares of the company's stock worth $906,000 after purchasing an additional 121,326 shares in the last quarter. Millennium Management LLC increased its stake in shares of Ginkgo Bioworks by 113.1% during the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock worth $8,137,000 after purchasing an additional 757,535 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Ginkgo Bioworks by 25.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock worth $3,915,000 after purchasing an additional 139,126 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Ginkgo Bioworks in the 1st quarter valued at approximately $120,000. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.